REBEKAH MONTGOMERY: Open Payments
NPI 1215482195 · SHERIDAN, WY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 41 payments from 11 companies in 2025. Trend: 2023 $611 · 2024 $531 · 2025 $702
Food & beverage: $697Education: $5
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 16 | $144 |
| AstraZeneca Pharmaceuticals LP | 8 | $138 |
| Astellas Pharma US Inc | 3 | $84 |
| Madrigal Pharmaceuticals | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| Edwards Lifesciences Corporation | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Novo Nordisk Inc | 2 | $35 |
| Amgen Inc. | 2 | $33 |
| ABBVIE INC. | 1 | $32 |
Products named: MOUNJARO, BREZTRI, Veozah, REZDIFFRA, CAPLYTA, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), DUPIXENT, UBRELVY.
Industry payments across WY — which companies pay providers there.
